Therapeutic Effects of Curcumin Derivatives against Obesity and Associated Metabolic Complications: A Review of In Vitro and In Vivo Studies
暂无分享,去创建一个
C. Pheiffer | Salam J.J. Titinchi | B. Jack | S. Mazibuko-Mbeje | Marakiya T. Moetlediwa | Rudzani Ramashia
[1] Csaba Rácz,et al. Strategies for Improving Bioavailability, Bioactivity, and Physical-Chemical Behavior of Curcumin , 2022, Molecules.
[2] N. Lipkovska,et al. Keto-enol tautomerism of curcumin in the preparation of nanobiocomposites with fumed silica. , 2022, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
[3] Takwa Bedhiafi,et al. Curcumin and Derivatives in Nanoformulations with Therapeutic Potential on Colorectal Cancer , 2022, AAPS PharmSciTech.
[4] Lei Wu,et al. In Vitro and In Vivo Cardioprotective Effects of Curcumin against Doxorubicin-Induced Cardiotoxicity: A Systematic Review , 2022, Journal of oncology.
[5] R. Rusinek,et al. Curcumin and Weight Loss: Does It Work? , 2022, International journal of molecular sciences.
[6] Luca Tiano,et al. Curcumin supplementation improves biomarkers of oxidative stress and inflammation in conditions of obesity, type 2 diabetes and NAFLD: updating the status of clinical evidence. , 2021, Food & function.
[7] M. Tschöp,et al. Anti-obesity drug discovery: advances and challenges , 2021, Nature reviews. Drug discovery.
[8] M. Balbaa,et al. Ameliorative effect of curcumin and zinc oxide nanoparticles on multiple mechanisms in obese rats with induced type 2 diabetes , 2021, Scientific Reports.
[9] Huadong Tang,et al. Curc-mPEG454, a PEGylated curcumin derivative, as a multi-target anti-fibrotic prodrug. , 2021, International immunopharmacology.
[10] N. Chattipakorn,et al. Curcumin analogue C66 attenuates obesity-induced myocardial injury by inhibiting JNK-mediated inflammation. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[11] S. Kim,et al. Dehydrozingerone inhibits renal lipotoxicity in high‐fat diet–induced obese mice , 2021, Journal of cellular and molecular medicine.
[12] Bin Yang,et al. Curcumin analogue C66 attenuates obesity-induced renal injury by inhibiting chronic inflammation. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[13] Chiadi E. Ndumele,et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association , 2021, Circulation.
[14] R. V. van Breemen,et al. Pharmacokinetics of a Single Dose of Turmeric Curcuminoids Depends on Formulation: Results of a Human Crossover Study , 2021, The Journal of nutrition.
[15] X. Liao,et al. Curcumin prevents obesity by targeting TRAF4‐induced ubiquitylation in m6A‐dependent manner , 2021, EMBO reports.
[16] H. Zimdahl,et al. Challenges in tackling energy expenditure as obesity therapy: From preclinical models to clinical application , 2021, Molecular metabolism.
[17] S. Y. Lee,et al. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? , 2021, Current Obesity Reports.
[18] P. Somvanshi,et al. Reductive metabolites of curcumin and their therapeutic effects , 2020, Heliyon.
[19] Yan-qiang Liu,et al. Curcumin anti-diabetic effect mainly correlates with its anti-apoptotic actions and PI3K/Akt signal pathway regulation in the liver. , 2020, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[20] Elise Adrian Ostrander,et al. Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications , 2020, Frontiers in Pharmacology.
[21] P. Matafome,et al. Curcumin derivatives for Type 2 Diabetes management and prevention of complications , 2020, Archives of Pharmacal Research.
[22] A. Naiki‐Ito,et al. Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo , 2020, Molecules.
[23] C. Ballantyne,et al. Metabolic Inflammation and Insulin Resistance in Obesity , 2020, Circulation research.
[24] S. Ray,et al. Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review , 2020, Molecules.
[25] K. Skalicka‐Woźniak,et al. Bioactivity of dietary polyphenols: The role of metabolites , 2020, Critical reviews in food science and nutrition.
[26] Xing Tang,et al. Pharmaceutical strategies of improving oral systemic bioavailability of curcumin for clinical application. , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[27] Hong-Min Kim,et al. Curcumin analog CUR5-8 ameliorates nonalcoholic fatty liver disease in mice with high-fat diet-induced obesity. , 2019, Metabolism: clinical and experimental.
[28] R. El-Shishtawy,et al. Curcumin analogues and their hybrid molecules as multifunctional drugs. , 2019, European journal of medicinal chemistry.
[29] A. Dömling,et al. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes , 2019, Journal of Translational Medicine.
[30] R. Ghidoni,et al. Dietary Curcumin: Correlation between Bioavailability and Health Potential , 2019, Nutrients.
[31] Bradley S. Fleenor,et al. Influence of enhanced bioavailable curcumin on obesity-associated cardiovascular disease risk factors and arterial function: A double-blinded, randomized, controlled trial. , 2019, Nutrition.
[32] Kok-Gan Chan,et al. Curcumin Nanoformulations for Colorectal Cancer: A Review , 2019, Front. Pharmacol..
[33] C. Mantzoros,et al. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. , 2019, Metabolism: clinical and experimental.
[34] A. Stefanović,et al. Obesity and dyslipidemia. , 2019, Metabolism: clinical and experimental.
[35] S. Nabavi,et al. Mechanistic insights of hepatoprotective effects of curcumin: Therapeutic updates and future prospects. , 2019, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[36] K. Davis,et al. Early and late complications of bariatric operation , 2018, Trauma Surgery & Acute Care Open.
[37] Amirhossein Sahebkar,et al. Therapeutic potential of curcumin in diabetic complications , 2018, Pharmacological research.
[38] Yong Chen,et al. The pharmacokinetics and tissue distribution of curcumin and its metabolites in mice. , 2018, Biomedical chromatography : BMC.
[39] F. Ursini,et al. Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial , 2018, Pharmacological research.
[40] A. Sahebkar,et al. Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review , 2018, Phytotherapy research : PTR.
[41] Huadong Tang,et al. Curc-mPEG454, a PEGylated Curcumin Derivative, Improves Anti-inflammatory and Antioxidant Activities: a Comparative Study , 2017, Inflammation.
[42] G. Frühbeck,et al. Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way , 2017, Obesity Facts.
[43] D. Kalman,et al. Curcumin: A Review of Its’ Effects on Human Health , 2017, Foods.
[44] Qin Shen,et al. Transport of curcumin derivatives in Caco‐2 cell monolayers , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[45] Muheeb Beg,et al. Curcumin-3,4-Dichloro Phenyl Pyrazole (CDPP) overcomes curcumin's low bioavailability, inhibits adipogenesis and ameliorates dyslipidemia by activating reverse cholesterol transport. , 2017, Metabolism: clinical and experimental.
[46] Huadong Tang,et al. PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR-γ/CD36 Pathway , 2017, BioMed research international.
[47] Dongwei Zhang,et al. Recent Advances of Curcumin in the Prevention and Treatment of Renal Fibrosis , 2017, BioMed research international.
[48] X. Liu,et al. Diarylpentadienone derivatives (curcumin analogues): Synthesis and anti-inflammatory activity. , 2017, Bioorganic & medicinal chemistry letters.
[49] Jayme L. Dahlin,et al. The Essential Medicinal Chemistry of Curcumin , 2017, Journal of medicinal chemistry.
[50] T. Efferth,et al. Modulation of P-glycoprotein activity by novel synthetic curcumin derivatives in sensitive and multidrug-resistant T-cell acute lymphoblastic leukemia cell lines. , 2016, Toxicology and applied pharmacology.
[51] M. Sridhar,et al. Preventive effect of curcumin on inflammation, oxidative stress and insulin resistance in high-fat fed obese rats , 2016, Journal of complementary & integrative medicine.
[52] Gretchen A. Stevens,et al. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants , 2016, The Lancet.
[53] Chen Li,et al. Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer , 2016, Scientific Reports.
[54] S. Rivera-Mancía,et al. Experimental evidence for curcumin and its analogs for management of diabetes mellitus and its associated complications. , 2015, European journal of pharmacology.
[55] Xiaokun Li,et al. A Newly Designed Curcumin Analog Y20 Mitigates Cardiac Injury via Anti-Inflammatory and Anti-Oxidant Actions in Obese Rats , 2015, PloS one.
[56] J. O. Lee,et al. Dehydrozingerone exerts beneficial metabolic effects in high-fat diet-induced obese mice viaAMPK activation in skeletal muscle , 2015, Journal of cellular and molecular medicine.
[57] B. Aggarwal,et al. Curcumin Differs from Tetrahydrocurcumin for Molecular Targets, Signaling Pathways and Cellular Responses , 2014, Molecules.
[58] K. Priyadarsini. The Chemistry of Curcumin: From Extraction to Therapeutic Agent , 2014, Molecules.
[59] Alan D. Lopez,et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2014, The Lancet.
[60] Jun Ren,et al. Novel Curcumin Derivative CNB-001 Mitigates Obesity-Associated Insulin Resistance , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[61] L. Rao,et al. Structure-function activity of dehydrozingerone and its derivatives as antioxidant and antimicrobial compounds , 2014, Journal of Food Science and Technology.
[62] Zhe Wang,et al. Inhibition of MAPK-mediated ACE expression by compound C66 prevents STZ-induced diabetic nephropathy , 2013, Journal of cellular and molecular medicine.
[63] S. Esmaeili,et al. Obesity as an Important Risk Factor for Certain Types of Cancer , 2013, Iranian journal of cancer prevention.
[64] Xiaokun Li,et al. Targeting JNK by a New Curcumin Analog to Inhibit NF-kB-Mediated Expression of Cell Adhesion Molecules Attenuates Renal Macrophage Infiltration and Injury in Diabetic Mice , 2013, PloS one.
[65] Jin‐Ming Lin,et al. Analysis of keto-enol tautomers of curcumin by liquid chromatography/mass spectrometry , 2013 .
[66] H. Ishihara. Current status and prospects of polyethyleneglycol-modified medicines. , 2013, Biological & pharmaceutical bulletin.
[67] S. Rössner,et al. Obesity management: what brings success? , 2013, Therapeutic advances in gastroenterology.
[68] A. Al-Malki,et al. Effect of novel water soluble curcumin derivative on experimental type- 1 diabetes mellitus (short term study) , 2012, Diabetology & Metabolic Syndrome.
[69] Xiaokun Li,et al. Inhibition of high glucose‐induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats , 2012, British journal of pharmacology.
[70] Salma Khan,et al. Curcumin molecular targets in obesity and obesity-related cancers. , 2012, Future oncology.
[71] K. Tomita-Yokotani,et al. Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism , 2011, Proceedings of the National Academy of Sciences.
[72] J. Mckim,et al. CeeTox™ Analysis of CNB-001 a Novel Curcumin-Based Neurotrophic/Neuroprotective Lead Compound to Treat Stroke: Comparison with NXY-059 and Radicut , 2011, Translational Stroke Research.
[73] T. Kálai,et al. Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties , 2010, Cancer biology & therapy.
[74] B. Zhang,et al. Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects. , 2010, Nanomedicine.
[75] S. Vareed,et al. Pharmacokinetics of Curcumin Conjugate Metabolites in Healthy Human Subjects , 2008, Cancer Epidemiology Biomarkers & Prevention.
[76] P. Maher,et al. A broadly neuroprotective derivative of curcumin , 2008, Journal of neurochemistry.
[77] T. Tsai,et al. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[78] P. Mukherjee,et al. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. , 2007, International journal of pharmaceutics.
[79] Daniel Normolle,et al. Dose escalation of a curcuminoid formulation , 2006, BMC complementary and alternative medicine.
[80] W. Shin,et al. Synthesis of novel curcumin mimics with asymmetrical units and their anti-angiogenic activity. , 2005, Bioorganic & medicinal chemistry letters.
[81] V. Menon,et al. Comparative effects of curcumin and its analog on alcohol- and polyunsaturated fatty acid-induced alterations in circulatory lipid profiles. , 2005, Journal of medicinal food.
[82] S. Jachak,et al. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. , 2005, Bioorganic & medicinal chemistry letters.
[83] V. Menon,et al. Protective Role of a Novel Curcuminoid on Alcohol and PUFA-Induced Hyperlipidemia , 2005, Toxicology mechanisms and methods.
[84] Thorsteinn Loftsson,et al. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. , 2002, International journal of pharmaceutics.
[85] D. Scholz,et al. Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. , 1999, Journal of ethnopharmacology.
[86] Jen-kun Lin,et al. Biotransformation of curcumin through reduction and glucuronidation in mice. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[87] M. Majeed,et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. , 1998, Planta medica.
[88] K. N. Rajasekharan,et al. Antimutagenic and anticarcinogenic activity of natural and synthetic curcuminoids. , 1996, Mutation research.
[89] K. N. Rajasekharan,et al. SIMPLIFIED CONDITION FOR SYNTHESIS OF CURCUMIN I AND OTHER CURCUMINOIDS , 1994 .
[90] V. Lampe,et al. Studien über Curcumin , 1913 .
[91] Ayman El-Meghawry El-Kenawy,et al. Tumeric or Curcuma longa Linn. , 2019, Nonvitamin and Nonmineral Nutritional Supplements.
[92] Adrian L. Lopresti. The Problem of Curcumin and Its Bioavailability: Could Its Gastrointestinal Influence Contribute to Its Overall Health-Enhancing Effects? , 2018, Advances in nutrition.
[93] Havva Sezer,et al. Insulin Resistance, Obesity and Lipotoxicity. , 2017, Advances in experimental medicine and biology.
[94] K. Kathiresan,et al. Curcumin–Piperine/Curcumin–Quercetin/Curcumin–Silibinin dual drug-loaded nanoparticulate combination therapy: A novel approach to target and treat multidrug-resistant cancers , 2013 .
[95] V. Menon,et al. Antioxidant and anti-inflammatory properties of curcumin. , 2007, Advances in experimental medicine and biology.
[96] Donald J L Jones,et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[97] J. Miłobȩdzka,et al. Zur Kenntnis des Curcumins , 1897 .